Problem Faced

Atrial fibrillation is a heart abnormality that affects 2.2 million Americans.

Company Background

o Medical device start-up

o Located in Santa Clara

o Founded in 2006

o Manufactures cardiac medical instruments

o Developing new treatment for a heart condition called atrial fibrillation (a heart abnormality that affects 2.2 million Americans)

Innovation

Voyage Medical’s technique improve on existing treatments because it allows doctors to perform “radiofrequency ablation” under direct visualization.

o Currently developing a minimally invasive platform to enable electrophysiologist, cardiologist or surgeons to view the interior of a live heart through blood, while performing complex heart procedures under real time in vivo visualization. (other alternatives to AF treatment: http://en.wikipedia.org/wiki/Atrial_fibrillation#Treatment)

Competitive Advantages

3 patents

Voyage Medical, Inc.

CAMPBELL, CA US

20080281293 COMPLEX SHAPE STEERABLE TISSUE VISUALIZATION AND MANIPULATION CATHETER 11-13-2008
2. 20080275300 COMPLEX SHAPE STEERABLE TISSUE VISUALIZATION AND MANIPULATION CATHETER 11-06-2008
3. 20080214889 METHODS AND APPARATUS FOR PREVENTING TISSUE MIGRATION 09-04-2008

Financials

Voyage Medical a Santa Clara cardiac medical device company, has raised around $3.44 million in Series A funding led by RWI Ventures, according to a regulatory filing cited.

Voyage Medical, which is developing new treatment for a heart condition called atrial fibrillation, has raised $22 million in a second round of financing. New investor Three Arch Partners led the round, with participation from Kleiner Perkins Caulfield & Byers (also a new investor) and existing investor RWI Ventures, according to VentureWire.

More info on Speaker:

Vahid Saadat Founder, CEO Voyage Medical

Vahid Saadat has over 20 years of experience in the medical device industry. Currently Mr. Saadat is the founder and CEO of Voyage Medical in Santa Clara, California which he founded in February of 2006. Previously, Mr. Saadat co-founded and was the president of USGI Medical, Inc a gastrointestinal device company backed by Alta partners and Interwest partners. Mr. Saadat is also a co-founder and a board member of Baxano, Inc, an orthopedic and spine Company backed by Prospect Venture Partners and Three Arch Partners. Baxano was founded in July of 2005. Before USGI Medical, Mr. Saadat served as the president and CEO of AngioTrax, founded in 1997. AngioTrax developed myocardial revascularization technologies for the treatment of ischemic heart disease. Prior to AngioTrax, Mr. Saadat served as Vice President of Research and Development at Gynecare, Inc. Gynecare was acquired by Johnson and Johnson in 1997. Prior to Gynecare, Mr. Saadat was Senior Vice President of R&D and operations at Trimedyne, Inc., where he managed the development of new laser technologies. Mr. Saadat also helped found Cardiac Science, which developed an automatic defibrillator device and is now a public company. Mr. Saadat holds a BS and MS in Electrical and Biomedical engineering from the University of Texas at Austin. He has many scientific publications to his credit and is inventor on over 200 issued and pending patents.

This entry was posted on Monday, December 8th, 2008 at 4:52 am and is filed under Organizational Writeups. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.